Literature DB >> 8934378

Cost-effectiveness calculations from trials.

E Ambrosioni1, F V Costa.   

Abstract

EFFECTIVENESS OF ANTIHYPERTENSIVE THERAPY: Data on the effectiveness of antihypertensive therapy derived from the results of large clinical trials are of great importance, but also have a number of significant flaws and probably underestimate the real effectiveness of treatment. In the next few years much more information is likely to become available on the effects of the newer classes of drugs and thus evaluations of cost-effectiveness will have fewer limitations than at present. ECONOMIC VALUE OF SAVING A LIFE: Today, in every country worldwide, priority should be given to determining the economic cost of avoiding the morbidity and mortality caused by hypertension. Each society must decide the price per life-year gained that it is willing to pay. This is the most difficult task of all, since the economic value of saving a life is not easily evaluable.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8934378     DOI: 10.1097/00004872-199609002-00011

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  6 in total

Review 1.  Cost per millimeter of mercury lowering is a measure of economic value for antihypertensive agents.

Authors:  R S Chen; P Lapuerta
Journal:  Curr Hypertens Rep       Date:  2000-12       Impact factor: 5.369

Review 2.  Pharmacoeconomics of hypertension management: the place of combination therapy.

Authors:  E Ambrosioni
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

3.  Compliance with therapy in hypertensive patients.

Authors:  Claudio Borghi
Journal:  Intern Emerg Med       Date:  2006       Impact factor: 3.397

Review 4.  Pharmacoeconomic considerations in the management of hypertension.

Authors:  H Pardell; R Tresserras; P Armario; R Hernández del Rey
Journal:  Drugs       Date:  2000       Impact factor: 9.546

5.  Epidemiology of essential hypertension: the role of genetic polymorphism.

Authors:  V Romano-Spica; M Mettimano; A Ianni; M L Specchia; G Ricciardi; L Savi
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

6.  Economic aspects of hypertension treatment in Poland.

Authors:  Jana Krzysztoszek; Dorota Koligat; Piotr Ratajczak; Wiesław Bryl; Maciej Cymerys; Karolina Hoffmann; Ewelina Wierzejska; Paweł Kleka
Journal:  Arch Med Sci       Date:  2013-01-21       Impact factor: 3.318

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.